Need help paying for your SYLVANT® (siltuximab) prescription?
We want to guide you to programs that may help. Here you'll find the financial assistance programs available for SYLVANT®. We have also listed most of the eligibility requirements for each, so you can narrow your focus to those that best suit your circumstances. Call the programs or visit their websites to learn more.
You may be eligible for one or more of the following programs:
At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.
The following programs are affiliated with Janssen.
They are updated on a regular basis. Be sure to visit the program site for additional information.
Janssen CarePath Savings Program for SYLVANT®
If you have commercial or private health insurance and need help paying for SYLVANT®, the Janssen CarePath Savings Program for SYLVANT® may provide a rebate for your out-of-pocket SYLVANT® costs. If eligible, you may receive a rebate for your out-of-pocket SYLVANT® medication expenses after you pay your full copay amount to your healthcare provider when you receive your treatment. You will receive a rebate up to $1,000 per infusion for your medication costs and will pay $50 per infusion. Costs of IV infusion services are not covered by this program. Program exhausts 12 months from your first eligible date of service. You may re-enroll annually to continue receiving a benefit from the program. If you are using Medicare, Medicaid, TRICARE, or other federal or state healthcare plan to pay for SYLVANT® medication, you are not eligible to participate in this program. Click here for more information on the Rebate Program in general, or here for enrollment information.
Eligibility Requirements for Janssen CarePath Savings Program for SYLVANT®
You may be eligible if:
You have been prescribed SYLVANT®
You currently have commercial or private health insurance that covers medication costs for SYLVANT®
You are not using Medicare, Medicaid, TRICARE, or other federal or state healthcare plan to pay for SYLVANT® medication, including pharmaceutical assistance programs
The following programs are not affiliated with Janssen.
Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.
Johnson & Johnson Patient Assistance Foundation
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals who do not have insurance coverage for their medicines and do not have adequate financial resources to pay for them. Please contact a JJPAF program specialist at 800-652-6227 (9 AM to 6 PM ET) or visit the foundation website at JJPAF.org to see if you might qualify for assistance.
Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and coinsurance. Find out if your state has a program that can help you.
Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.
Those who are eligible for LIS may:
Receive assistance paying their monthly premium
Have a reduced or no deductible
Have reduced or no prescription coinsurance and co-payments
SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman's disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.
It is not known if SYLVANT® is safe and effective in children.
Who should not receive SYLVANT®?
Do not receive SYLVANT® if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT®.
What should I tell my healthcare provider before receiving SYLVANT®?
Before you receive SYLVANT®, tell your healthcare provider about all of your medical conditions, including if you:
have an infection. You should not receive SYLVANT® if you have a severe infection.
have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT®.
have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.
are pregnant or plan to become pregnant. It is not known if SYLVANT® will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT®. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT® and for 3 months after stopping treatment.
are breastfeeding or plan to breastfeed. It is not known if SYLVANT® passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT® or breastfeed. You should not do both.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SYLVANT®?
SYLVANT® may cause serious side effects, including:
Infections. SYLVANT® may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT®.
Infusion and allergic reactions. If you have an infusion or allergic reaction while receiving SYLVANT®, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT®: trouble breathing, chest tightness, wheezing, dizziness or light-headedness, swelling of the lips, or skin rash.
The most common side effects of SYLVANT® include: rash, itching, upper respiratory tract infection, weight gain, and increased blood level of uric acid.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of SYLVANT®.
Call your doctor for medical advice about side effects.
General information about the safe and effective use of SYLVANT®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about SYLVANT® that is written for health professionals.
Report any signs of new or worsening medical conditions to your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to the FDA.
SYLVANT® (siltuximab) is a prescription medicine used to treat people with multicentric Castleman's disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection.
It is not known if SYLVANT® is safe and effective in children.
Who should not receive SYLVANT®?
Do not receive SYLVANT® if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT®.
What should I tell my healthcare provider before receiving SYLVANT®?
Before you receive SYLVANT®, tell your healthcare provider about all of your medical conditions, including if you:
have an infection. You should not receive SYLVANT® if you have a severe infection.
have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT®.
have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.
are pregnant or plan to become pregnant. It is not known if SYLVANT® will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT®. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT® and for 3 months after stopping treatment.
are breastfeeding or plan to breastfeed. It is not known if SYLVANT® passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT® or breastfeed. You should not do both.
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of SYLVANT®?
SYLVANT® may cause serious side effects, including:
Infections. SYLVANT® may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT®.
Infusion and allergic reactions. If you have an infusion or allergic reaction while receiving SYLVANT®, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT®: trouble breathing, chest tightness, wheezing, dizziness or light-headedness, swelling of the lips, or skin rash.
The most common side effects of SYLVANT® include: rash, itching, upper respiratory tract infection, weight gain, and increased blood level of uric acid.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of SYLVANT®.
Call your doctor for medical advice about side effects.
General information about the safe and effective use of SYLVANT®
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about SYLVANT® that is written for health professionals.
Report any signs of new or worsening medical conditions to your healthcare provider.
You are encouraged to report negative side effects of prescription drugs to the FDA.
